Today, Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTACTM (Regulated Induced Proximity Targeting Chimeras) therapeutics, announced that it has raised new financing of $126 million in a Series B extension. This funding propels a novel approach in precision oncology, offering hope for cancer patients who need new and effective treatments. Congratulations to the Halda team! Learn more: https://bwnews.pr/3AjiypQ #VidaPortfolio #HoldandKillCancer
Our new financing sets a clear path for Halda to advance #RIPTACtherapeutics into the clinic for two major solid tumors types – prostate cancer and breast cancer. With the backing of premier investors, including Vida Ventures, LLC and Arjun Goyal, M.D., our novel RIPTAC candidates are designed to overcome drug resistance and improve outcomes for cancer patients. #HoldandKillCancer #CancerResearch https://lnkd.in/eQYsgXxC